Chemokine Therapeutics Supplies NCI With Investigational Compound
Posted on: Wednesday, 15 February 2006, 06:00 CST
Chemokine Therapeutics has reached an agreement to supply its investigational compound, CTCE-9908, to the National Cancer Institute, so that its potential in a rare form of cancer can be evaluated.
The researchers at the NCI will investigate the role of CTCE-9908 in the pathology of primary effusion lymphoma (PEL), a rare form of non-Hodgkin lymphoma that is usually associated with human immunodeficiency virus infections (HIV).
This aggressive type of lymphoma presents primarily in advance-stage HIV-infected individuals whose disease grows and spreads primarily in the body cavity. In patients, the clinical course for this disease is often aggressive, more extensive, and less responsive to chemotherapy.
The new agreement with the NCI marks the first exploration of a series of preclinical studies in a lymphoma cell line, the results of which will help direct future strategies in clinical trials.
CTCE-9908 has shown promising results against several cancer types in preclinical models including lung, prostate and bone cancers.
Source: Datamonitor
Related Articles
- Chemokine Therapeutics Announces Breast Cancer Data Presented at a Metastasis Conference With Lead Compound, CTCE-9908
- Chemokine Therapeutics Announces Liver Cancer Data Presented at the AACR Meeting on Its Lead Compound, CTCE-9908
- Chemokine Therapeutics Announces Positive Data Presented at the AACR Annual Meeting on Lead Product Candidate CTCE-9908
- Dr. Anthony Tolcher to Speak at the AACR Annual Meeting on Chemokine Therapeutic's Lead Drug Candidate CTCE-9908
- Chemokine Therapeutics Announces Three Abstracts Accepted for Presentation at the AACR Annual Meeting on Its Lead Drug Candidate CTCE-9908
- Chemokine Therapeutics Continues Patient Therapy Using CTCE-9908 and Extends Closing of Its Phase I/II Clinical Trial
- Chemokine Therapeutics Investigator Presents Encouraging Preliminary Results From CTCE-9908 Phase I/II Clinical Trial
- Chemokine Therapeutics Completes Patient Recruitment of CTCE-9908 Phase I/II Clinical Trial
- Chemokine Therapeutics Announces Preliminary Results of CTCE-9908 Phase Ib/II Clinical Trial in Late Stage Cancer Patients
- Immune System Finding Paves Way for Vaccine Use in Some Leukemia, Lymphoma Cancers
 |
 |
User Comments (0)
RSS Feeds